A Study Comparing Swallowed Flovent and Placebo in Patients With Eosinophilic Disorders

Overview

The purpose of this study is assessing the efficacy of swallowed Flovent® vs. placebo for the treatment of eosinophilic esophagitis (EE).

Full Title of Study: “Effect of Swallowed Fluticasone Propionate on Eosinophilic Esophagitis; A Prospective, Randomized, Placebo-Controlled Trial”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
  • Study Primary Completion Date: November 2006

Interventions

  • Drug: Fluticasone Propionate
    • Flovent vs. placebo daily for 3 months

Clinical Trial Outcome Measures

Primary Measures

  • Histologic remission
    • Time Frame: 5 years
    • Histologic remission,defined by a peak eosinophil count of less than/equal to 1 eosinophil in all 400 fields in both the proximal and distal esophagus.

Secondary Measures

  • Furrowing, Epithelial hyperplasia, clinical symptoms
    • Time Frame: 5 years
    • Secondary outcome measures included presence of endoscopic furrowing, presence of epithelial hyperplasia, and presence of clinical symptoms.

Participating in This Clinical Trial

Inclusion Criteria

  • Signed informed consent for study by parent or guardian. Assent will be obtained from all minors 11 years of age and older. – Age older than or equal to 3 years and younger than or equal to 30 years – Endoscopic findings consistent with EE (edema, furrowing, exudates, rings) – Histological findings to include proliferation of basal layer and peak eosinophil density ≥24 per high power field (400x). This degree of tissue eosinophilia has been shown to correlate well with poor-responsiveness to acid suppression therapy, suggesting it is a primary eosinophilic disease and not secondary to GERD[11]. – Allergy evaluation including skin-prick testing with multiple food antigens to insure elimination diet is not indicated. – If allergic to specific foods, option to be on a minimum 3 months of elimination diet without detectable resolution by repeat endoscopy with biopsies demonstrating no improvement to disease. – Patients enrolled at CCHMC will be under the direct care of Dr. Putnam or any of the other staff gastroenterologists at this institution who will supervise endoscopic procedures. Patients may also be enrolled at institutions other than CCHMC, but the diagnosis of EE must be validated by an expert pathologist in EE at CCHMC (Margaret Collins, MD). – 20 additional patients without EE will be enrolled as unaffected controls for purposes of comparison with patients with EE. Enrollment pool will comprise patients undergoing routine upper endoscopy and having no identifiable pathology. Exclusion Criteria:

  • Patients with history of poor tolerance to FP, patients unable to cooperate with use of MDI, pregnant females, patients inhaling any corticosteroid for asthma, and patients with concurrent or recent (within 3 months) use of systemic steroids.

Gender Eligibility: All

Minimum Age: 3 Years

Maximum Age: 30 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Marc Rothenberg
  • Provider of Information About this Clinical Study
    • Sponsor-Investigator: Marc Rothenberg, MD, PhD – Children’s Hospital Medical Center, Cincinnati
  • Overall Official(s)
    • Marc E. Rothenberg, M.D., Ph.D., Principal Investigator, Children’s Hospital Medical Center, Cincinnati

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.